Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caplin Point LaboratoriesNSE:CAPLIPOINT -1.56%88 Return-on-Tangible-Asset is 17.05% as of Mar. 2026, which is 13% below its 10-year median of 19.51. GuruFocus rates NSE:CAPLIPOINT with a GF Score™ of 88/100 and a GF Value™ of ₹2,093.16 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Caplin Point Laboratories ranks better than 92.95% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Caplin Point Laboratories's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹6,804 Mil. Caplin Point Laboratories's average total tangible assets for the quarter that ended in Mar. 2026 was ₹39,917 Mil. Therefore, Caplin Point Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 17.05%.
The historical rank and industry rank for Caplin Point Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
NSE:CAPLIPOINT'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 17.85 Med: 19.51 Max: 33.85
Current: 18.04
During the past 13 years, Caplin Point Laboratories's highest Return-on-Tangible-Asset was 33.85%. The lowest was 17.85%. And the median was 19.51%.
NSE:CAPLIPOINT's Return-on-Tangible-Asset is ranked better than 92.95% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs NSE:CAPLIPOINT: 18.04
Caplin Point Laboratories (NSE:CAPLIPOINT) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Caplin Point Laboratories Return-on-Tangible-Asset Related Terms
Caplin Point Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Caplin Point Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caplin Point Laboratories Return-on-Tangible-Asset Chart
NSE:CAPLIPOINT vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caplin Point Laboratories Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Caplin Point Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 17.05% mean?
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Return-on-Tangible-Asset of 17.05% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Caplin Point Laboratories and its competitors. This is 13% below median its historical median of 19.51. Over the past decade, Caplin Point Laboratories' Return-on-Tangible-Asset has ranged from 17.85 to 33.85. According to the industry distribution chart, Caplin Point Laboratories ranks #71 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 7.1%.
Is Caplin Point Laboratories' Return-on-Tangible-Asset too high?
Caplin Point Laboratories' current Return-on-Tangible-Asset of 17.05% is 13% below median its 10-year median of 19.51. Over the past 10 years, this metric has ranged from a low of 17.85 to a high of 33.85. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Caplin Point Laboratories' value of 17.05% is 441.3% above this industry median. Based on the distribution chart, Caplin Point Laboratories ranks #71 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Caplin Point Laboratories has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #71 out of 1007 companies for Return-on-Tangible-Asset. This places Caplin Point Laboratories in the top 7% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. Caplin Point Laboratories' value of 17.05% is 441.3% above this benchmark. Historically, Caplin Point Laboratories' own Return-on-Tangible-Asset has ranged from 17.85 to 33.85 over the past decade. While the company's 10-year median is 19.51 vs. the industry median of 3.15, Caplin Point Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caplin Point Laboratories's current Return-on-Tangible-Asset of 17.05% is 441.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Caplin Point Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current Return-on-Tangible-Asset is 17.05%, which is 13% below median its own 10-year median of 19.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,093.16, compared to a current price of ₹2,608.00 — trading 24.6% above its estimated fair value. The current Return-on-Tangible-Asset is 17.05%, which is 13% below median its 10-year median of 19.51 and 441.3% above the Drug Manufacturers industry median of 3.15. Caplin Point Laboratories' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Return-on-Tangible-Asset is 17.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued.
The current stock price of ₹2,608.00 is trading 24.6% above its estimated GF Value™ of ₹2,093.16.
GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:CAPLIPOINT:
Return-on-Tangible-Asset: 17.05% (13% below median its 10-year median of 19.51)
GF Value™: ₹2,093.16 vs. price of ₹2,608.00 (24.6% above fair value)
Industry Position: 441.3% above the Drug Manufacturers median (#71 of 1007)
No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
88GF Score
Get the complete analysis for NSE:CAPLIPOINT
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAPLIPOINT has been successfully added to your 
